The Ascension Life Fund is a specialist early-stage EIS fund focussing on the UK HealthTech and Life Sciences sectors.
Since launching in January, the Life Fund has made five investments with another Term Sheet agreed. These investments include Novai (a retinal biomarker for the early detection of eye disease), Stablepharma (vaccine stabilisation technology), Pangaea Data (AI/ML to extract intelligence from health data), MedAll (training and certification for healthcare professionals), and ExSeed (male fertility tracking and monitoring).
In terms of stage, the fund invests at post-seed, pre-Series A and is happy to act as the Lead Investor. We look for companies with strong IP, balanced teams and technical/scientific validation. We focus on companies who are selling to the pharmaceutical industry and do not invest in single asset drug development or wellbeing. We look for a ‘double bottom line’ whereby portfolio companies benefit humanity as well as the prospect of financial returns.
The Ascension Life Fund combines the domain expertise of the Investment Team and Advisors with Ascension’s reputation, operational experience, and track record. We believe that this gives the Fund advantages at each stage of the investment lifecycle (sourcing, selection, due diligence, post-investment support all the way to exit).
Our Investor Overview presentation provides more detail about the Investment Thesis, Team, Portfolio, and Ascension’s Track Record. We have an extremely strong pipeline which we would be happy to discuss with interested parties.
The Ascension Life Fund is an evergreen fund with ambitions to be a major player in the early-stage UK HealthTech and Life Sciences space. We have made great progress in a short period of time and are quickly building a reputation as a smart-money, value-add investor.